ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Psychedelic-Assisted Therapy Offers New Hope for Veterans

MISSION, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- (Family Features) For generations, America’s veterans have borne not only the visible scars of battle but also the hidden wounds of war. Post-traumatic stress disorder (PTSD), depression, traumatic brain injury and anxiety have long haunted those who served, often with devastating effects on their quality of life and their families. While traditional treatments have helped, many veterans continue to suffer in silence – left behind by a system struggling to meet their needs.

17707

However, science is now reopening doors once closed, and therapies previously dismissed are being reconsidered with fresh eyes. Among them are psychedelic-assisted treatments, which have revealed potential in clinical trials to address the most severe mental health conditions afflicting veterans.

The FDA’s Role
Currently, the Food and Drug Administration (FDA) has approved only one psychedelic-based medication: a ketamine nasal spray to treat depression. However, other compounds are gaining the attention of researchers, clinicians and veterans alike. Psilocybin – the active ingredient in “magic mushrooms” – and a drug similar to LSD have both earned FDA “breakthrough therapy” status for their potential to ease depression and anxiety, sometimes after only a single dose.

In 2017, MDMA-assisted therapy was identified as a potential breakthrough treatment option for PTSD; ultimately, the FDA declined to grant full approval. This setback underscored not a failure of science, but the complexity of studying powerful compounds under existing regulatory frameworks. For veterans, it was a disappointment, yet it also spotlighted the urgent need for continued research and funding.

Veterans and Research at the Forefront
One compound has captured national attention: ibogaine, a psychedelic root traditionally used in ceremonies in central and west Africa. Early studies with special-operations veterans have found improvements in PTSD, depression, anxiety and overall functioning – especially for those living with the effects of traumatic brain injury.

Recognizing this potential, DAV (Disabled American Veterans) is championing these new approaches. At its 2025 National Convention, the organization hosted a groundbreaking psychedelics roundtable that brought together researchers, veterans, advocates and even a former NFL player to discuss the potential of psychedelic-assisted therapies.

The century-old organization supports research into these treatments, pointing out that traditional therapies can fail for as many as 60% of those who try them. It’s also advocating for the Department of Veterans Affairs (VA) to make psychedelic treatments available once they receive FDA approval.

“We are experiencing a watershed moment in medical research as psychedelic-assisted therapies have revealed true potential in clinical trials to treat severe mental health conditions,” said Barry Jesinoski, DAV’s National Adjutant. “This glimmer offers veterans contending with not only PTSD but depression, traumatic brain injury, anxiety and more hope in a world where the status quo is failing them.”

A New Mission
The promising results of these treatments spurred some states to commit funding toward research into psychedelic therapies or conduct legislative hearings to explore their role in advancing this science. The VA is now conducting studies on MDMA and psilocybin.

While more research is needed to fully understand their risks, benefits and best applications, for DAV, psychedelic medication represents both hope and responsibility. By advocating for rigorous research and ensuring veterans’ perspectives are central to the conversation, the organization is working to accelerate progress while safeguarding integrity.

Whether through psilocybin, MDMA, ibogaine or future discoveries, the mission is clear: fund the research, pursue the science and ensure America’s veterans are given every chance to heal. Learn more at dav.org.

Photo courtesy of Shutterstock

Michael French
mfrench@familyfeatures.com 
1-888-824-3337
editors.familyfeatures.com

About Family Features Editorial Syndicate

A leading source for high quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more.  Find additional articles and information at culinary.net and eLivingToday.com. Family Features is a division of 4media group, the global strategic communications agency built for brands that want results.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bfb46028-8683-4076-a967-6f37e0b068bf


Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.12
+0.94 (0.39%)
AAPL  255.53
-2.68 (-1.04%)
AMD  231.83
+3.91 (1.72%)
BAC  52.97
+0.38 (0.72%)
GOOG  330.34
-2.82 (-0.85%)
META  620.25
-0.55 (-0.09%)
MSFT  459.86
+3.20 (0.70%)
NVDA  186.23
-0.82 (-0.44%)
ORCL  191.09
+1.24 (0.65%)
TSLA  437.50
-1.07 (-0.24%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.